MYCN and neuroblastoma: Specifically, loss of heterozygosity (LOH) in chromosome 11q (Ch 11q) in nonamplified-MYCN (NAMN) was found to be associated with a therapy-resistant metastatic NB subgroup [5] as well as with high activity of the cyclooxygenase (COX)/microsomal prostaglandin E synthase (mPGES)-1/PGE2 pathway [6].